DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Metzger-Filho O, Viale G, Trippa L. et al.
HER2 heterogeneity as apredictor of response to neoadjuvant T-DM1 plus Pertuzumab: Results from a prospective clinical trial. ASCO 2019.
J Clin Oncol 2019;
37 (Suppl. 15) 502a
We do not assume any responsibility for the contents of the web pages of other providers.